Biotech Values

[zipjet]

Actually, NVS/MNTA’s Copaxone ANDA becomes actionable in about three weeks, when the Hatch-Waxman 30-month stay expires. From that point on, the FDA can issue a final approval for the ANDA, not just a tentative approval.

Are there examples where FDA approved a generic while the patent litigation continued?

ij